Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity
Benjamin T. Bradley, Andrew Bryan, Susan L. Fink, Erin A. Goecker, Pavitra Roychoudhury, Meei‐Li Huang, Haiying Zhu, Anu Chaudhary, Bhanupriya Madarampalli, Joyce Lu, Kathy Strand, Estella Whimbey, Chloe Bryson‐Cahn, Adrienne Schippers, Nandita S Mani, Gregory Pepper, Keith R. Jerome, Chihiro Morishima, Robert W. Coombs, Mark H. Wener, Seth A. Cohen, Alexander L. Greninger
Abstract
With the availability of widespread SARS-CoV-2 vaccination, high-throughput quantitative antispike serological testing will likely become increasingly important. Here, we investigated the performance characteristics of the recently FDA-authorized semiquantitative antispike AdviseDx SARS-CoV-2 IgG II assay compared to the FDA-authorized antinucleocapsid Abbott Architect SARS-CoV-2 IgG, Roche Elecsys anti-SARS-CoV-2-S, EuroImmun anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA), and GenScript surrogate virus neutralization assays and examined the humoral response associated with vaccination, natural protection, and breakthrough infection.